Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP4401)
Name
Brusatol
Synonyms
Brusatol; 14907-98-3; Yatansin; (+)-Brusatol; CHEBI:3197; CHEMBL459546; (11beta,12alpha,15beta)-13,20-Epoxy-3,11,12-trihydroxy-15-((3-methyl-1-oxo-2-butenyl)oxy)-2,16-dioxopicras-3-en-21-oic acid, methyl ester; NSC 172924; BRN 1444847; (1R,2S,3S,3aS,3a1R,4R,6aR,7aR,11aS,11bR)-Methyl 1,2,9-trihydroxy-8,11a-dimethyl-4-((3-methylbut-2-enoyl)oxy)-5,10-dioxo-2,3,3a,4,5,6a,7,7a,10,11,11a,11b-dodecahydro-1H-3,3a1-(epoxymethano)dibenzo[de,g]chromene-3-carboxylate; Methyl 13,20-epoxy-3,11,12-trihydroxy-15-((3-methyl-1-oxo-2-butenyl)oxy)-2,16-dioxopicras-3-en-21-oate (11beta,12alpha,15beta)-; SCHEMBL1276480; Brusatol, >=95% (HPLC); DTXSID70164163; QCR-223; BCP15272; BDBM50535743; MFCD01746220; ZINC30726694; AKOS016013415; CS-W019658; 2H-3,11c-beta-(Epoxymethano)phenanthro(10,1-bc)pyran-3-alpha(3a-beta-H)-carboxylic acid, 1,4,5,6a-beta,7,7a-alpha,10,11,11a,11b-alpha-decahydro-8,11a-beta-dimethyl-5,10-dioxo-1-beta,2-alpha,4-beta,9-tetrahydroxy-, methyl ester, 4-(3-methylcrotonate); AS-55977; HY-19543; Picras-3-en-21-oic acid, 13,20-epoxy-3,11,12-trihydroxy-15-((3-methyl-1-oxo-2-butenyl)oxy)-2,16-dioxo-, methyl ester, (11beta,12alpha,15beta)-; C08754; Q27105985; methyl trihydroxy-dimethyl-(3-methylbut-2-enoyloxy)-dioxo-[?]carboxylate; Picras-3-en-21-oicacid,13,20-epoxy-3,11,12-trihydroxy-15-[(3-methyl-1-oxo-2-buten-1-yl)oxy]-2,16-dioxo-,methyl ester, (11b,12a,15b)-
    Click to Show/Hide
Species Origin Brucea javanica ...     Click to Show/Hide
Brucea javanica
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Sapindales
Family: Simaroubaceae
Genus: Brucea
Species: Brucea javanica
Disease Nasopharyngeal cancer [ICD-11: 2B6B] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C26H32O11
PubChem CID
73432
Canonical SMILES
CC1=C(C(=O)CC2(C1CC3C45C2C(C(C(C4C(C(=O)O3)OC(=O)C=C(C)C)(OC5)C(=O)OC)O)O)C)O
InChI
1S/C26H32O11/c1-10(2)6-15(28)37-18-20-25-9-35-26(20,23(33)34-5)21(31)17(30)19(25)24(4)8-13(27)16(29)11(3)12(24)7-14(25)36-22(18)32/h6,12,14,17-21,29-31H,7-9H2,1-5H3/t12-,14+,17+,18+,19+,20+,21-,24-,25+,26-/m0/s1
InChIKey
ZZZYHIMVKOHVIH-VILODJCFSA-N
CAS Number
CAS 14907-98-3
ChEBI ID
CHEBI:3197
Herb ID
HBIN018930
SymMap ID
SMIT00277
TCMSP ID
MOL008073
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Cisplatin      Bladder cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Up-regulation Expression BAX  Molecule Info 
Pathway MAP
                    In-vitro Model CT26 CVCL_7254 Mouse colon adenocarcinoma Mus musculus
                    Experimental
                    Result(s)
The combination of CDDP and BR was able to produce a synergistic antitumor effect in CRC cells, thus providing a solid foundation for further development of this combination regimen into an effective therapeutic method for CRC.
Target and Pathway
Target(s) Kelch-like ECH-associated protein 1 (KEAP1)  Molecule Info  [3]
Maleylacetoacetate isomerase (EIF5AL1)  Molecule Info  [4]
Nuclear factor erythroid 2-related factor 2 (Nrf2)  Molecule Info  [5]
Sequestosome-1 p62 (SQSTM1)  Molecule Info  [6]
KEGG Pathway Osteoclast differentiation Click to Show/Hide
2 Protein processing in endoplasmic reticulum
NetPath Pathway EGFR1 Signaling Pathway Click to Show/Hide
2 IL5 Signaling Pathway
Pathway Interaction Database IL1-mediated signaling events Click to Show/Hide
2 TNF receptor signaling pathway
3 p75(NTR)-mediated signaling
4 Neurotrophic factor-mediated Trk receptor signaling
Reactome NRIF signals cell death from the nucleus Click to Show/Hide
2 p75NTR recruits signalling complexes
3 NF-kB is activated and signals survival
4 Interleukin-1 signaling
WikiPathways Senescence and Autophagy in Cancer Click to Show/Hide
2 NRF2 pathway
3 Nuclear Receptors Meta-Pathway
4 Apoptosis-related network due to altered Notch3 in ovarian cancer
5 BDNF signaling pathway
6 RANKL/RANK Signaling Pathway
7 Signalling by NGF
8 IL-1 signaling pathway
9 Interleukin-1 signaling
10 Regulation of toll-like receptor signaling pathway
11 Oxidative Stress
12 Transcriptional activation by NRF2
13 Aryl Hydrocarbon Receptor Pathway
14 Mesodermal Commitment Pathway
15 Aryl Hydrocarbon Receptor
16 Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
17 Arylhydrocarbon receptor (AhR) signaling pathway
References
Reference 1 Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway. Cancer Chemother Pharmacol. 2020 Jun;85(6):1097-1108.
Reference 2 Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells. Int J Mol Med. 2018 Mar;41(3):1447-1454.
Reference 3 Resistance to gefitinib and cross-resistance to irreversible EGFR-TKIs mediated by disruption of the Keap1-Nrf2 pathway in human lung cancer cells. FASEB J. 2018 May 29:fj201800011R.
Reference 4 The protein synthesis inhibitor brusatol normalizes high-fat diet-induced glucose intolerance in male C57BL/6 mice: role of translation factor eIF5A hypusination. FASEB J. 2019 Mar;33(3):3510-3522.
Reference 5 Free heme regulates placenta growth factor through NRF2-antioxidant response signaling. Free Radic Biol Med. 2019 Nov 1;143:300-308.
Reference 6 Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia. Theranostics. 2017 Apr 10;7(7):1890-1900.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China